Inari Medical (NARI)
(Real Time Quote from BATS)
$49.44 USD
+1.91 (4.02%)
Updated Aug 15, 2024 03:55 PM ET
After-Market: $49.66 +0.22 (0.44%) 4:16 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Inari Medical, Inc. (NARI) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$65.92 | $93.00 | $50.00 | 38.69% |
Price Target
Based on short-term price targets offered by 12 analysts, the average price target for Inari Medical, Inc. comes to $65.92. The forecasts range from a low of $50.00 to a high of $93.00. The average price target represents an increase of 38.69% from the last closing price of $47.53.
Analyst Price Targets (12)
Broker Rating
Inari Medical, Inc. currently has an average brokerage recommendation (ABR) of 1.54 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 13 brokerage firms. The current ABR compares to an ABR of 1.64 a month ago based on 11 recommendations.
Of the 13 recommendations deriving the current ABR, nine are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 69.23% and 7.69% of all recommendations. A month ago, Strong Buy made up 63.64%, while Buy represented 9.09%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/NARI.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 7 | 7 | 7 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 3 | 3 | 3 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.54 | 1.54 | 1.64 | 1.50 | 1.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/31/2024 | Robert W. Baird & Co. | David Rescott | Strong Buy | Strong Buy |
7/31/2024 | Canaccord Genuity | William J Plovanic | Strong Buy | Strong Buy |
7/31/2024 | Wells Fargo Securities | Lawrence H Biegelsen | Strong Buy | Strong Buy |
7/25/2024 | William Blair | Margaret Kaczor | Not Available | Strong Buy |
7/18/2024 | Needham & Company | Michael Matson | Moderate Buy | Hold |
7/16/2024 | Truist Securities | Richard Newitter | Hold | Hold |
5/1/2024 | Piper Sandler | Adam C Maeder | Hold | Hold |
1/7/2024 | BTIG | Marie Thibault | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.54 |
ABR (Last week) | 1.54 |
# of Recs in ABR | 13 |
Average Target Price | $65.92 |
LT Growth Rate | NA |
Industry | Medical - Instruments |
Industry Rank by ABR | 80 of 253 |
Current Quarter EPS Est: | -0.11 |